TY - JOUR
T1 - Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy
AU - Dvoráková, Magdalena Chottová
AU - Pfeil, Uwe
AU - Kuncová, Jitka
AU - Švíglerová, Jitka
AU - Galvis, Giovanni
AU - Krasteva, Gabriela
AU - König, Peter
AU - Grau, Veronika
AU - Slavíková, Jana
AU - Kummer, Wolfgang
N1 - Funding Information:
Acknowledgements The authors thank Ms. P. Faulhammer, Ms. P. Freitag, Ms. G. Fuchs-Moll, Ms. J. Lodrová, Ms. K. Michael, Ms. T. Papadakis, Ms. K. Pícková, and Ms. S. Wiegand for skilful technical assistance. This study was supported by the Czech Science Foundation (GACR 305/01/0263, 305/03/D180), a governmental German-Czech cooperation grant (WTZ CZE 01/014), the German Research Foundation (DFG, Research Training Groups 534 and 1062), and a Young Scientist Award of the Faculty of Medicine, Justus Liebig University.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2006/3
Y1 - 2006/3
N2 - Vasoactive intestinal peptide (VIP) is a vasorelaxant peptide that addresses two receptor subtypes, VPAC1 and VPAC2. It stimulates insulin secretion and mediates anti-inflammatory effects and has been proposed for treatment of type 2 and autoimmune diabetes. In the heart, VIP is produced and released primarily by intrinsic neurons and improves cardiac perfusion and function. Here, we investigated the involvement of this system in the events underlying development of experimentally induced diabetic cardiomyopathy. Rats received a single streptozotocin injection, and cardiac VIP content [radioimmune assay (RIA)], expression of the VIP precursors VPAC1 and VPAC2 [real-time reverse transcription-polymerase chain reaction (RT-PCR)], and VPAC1 and VPAC2 tissue distribution (immunohistochemistry) were assessed 4, 8, and 16 weeks thereafter and compared with corresponding vehicle-treated controls. Cardiac neuropathy manifests progressively during the first 4 months of diabetes at the preproVIP mRNA and VIP peptide level and is accompanied by initial down-regulation of VPAC2 at one prime target of VIP-containing axons, i.e., smooth muscle cells of coronary arterioles. VPAC1 is expressed by macrophages. After initial changes that are specific for atria and ventricles, respectively, VPAC1 and VPAC2 expression return to control levels at 16 weeks despite ongoing loss of VIP. Given the cardioprotective role of the VIP signaling system, the persistence of receptors has therapeutic implications since it is the prerequisite for trials with VPAC2 agonists.
AB - Vasoactive intestinal peptide (VIP) is a vasorelaxant peptide that addresses two receptor subtypes, VPAC1 and VPAC2. It stimulates insulin secretion and mediates anti-inflammatory effects and has been proposed for treatment of type 2 and autoimmune diabetes. In the heart, VIP is produced and released primarily by intrinsic neurons and improves cardiac perfusion and function. Here, we investigated the involvement of this system in the events underlying development of experimentally induced diabetic cardiomyopathy. Rats received a single streptozotocin injection, and cardiac VIP content [radioimmune assay (RIA)], expression of the VIP precursors VPAC1 and VPAC2 [real-time reverse transcription-polymerase chain reaction (RT-PCR)], and VPAC1 and VPAC2 tissue distribution (immunohistochemistry) were assessed 4, 8, and 16 weeks thereafter and compared with corresponding vehicle-treated controls. Cardiac neuropathy manifests progressively during the first 4 months of diabetes at the preproVIP mRNA and VIP peptide level and is accompanied by initial down-regulation of VPAC2 at one prime target of VIP-containing axons, i.e., smooth muscle cells of coronary arterioles. VPAC1 is expressed by macrophages. After initial changes that are specific for atria and ventricles, respectively, VPAC1 and VPAC2 expression return to control levels at 16 weeks despite ongoing loss of VIP. Given the cardioprotective role of the VIP signaling system, the persistence of receptors has therapeutic implications since it is the prerequisite for trials with VPAC2 agonists.
UR - http://www.scopus.com/inward/record.url?scp=32444442070&partnerID=8YFLogxK
U2 - 10.1007/s00441-005-0001-7
DO - 10.1007/s00441-005-0001-7
M3 - Journal articles
C2 - 16344947
AN - SCOPUS:32444442070
SN - 0302-766X
VL - 323
SP - 383
EP - 393
JO - Cell and Tissue Research
JF - Cell and Tissue Research
IS - 3
ER -
